BR112012021795A2 - método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica e malignidade de célula b associadas ao vírus de hepatite c (hvc), método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica ou malignidade de célula b associadas à infecção por vírus de hepatite c (hvc), método de tratamento de vasculite crioglobulinêmica e malignidade de célula b associadas a hcv em um sujeito, método de identificação de um sujeito que se encontra com risco de desenvolver malignidade associada ao vírus de hepatite c (hcv), e, kit - Google Patents

método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica e malignidade de célula b associadas ao vírus de hepatite c (hvc), método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica ou malignidade de célula b associadas à infecção por vírus de hepatite c (hvc), método de tratamento de vasculite crioglobulinêmica e malignidade de célula b associadas a hcv em um sujeito, método de identificação de um sujeito que se encontra com risco de desenvolver malignidade associada ao vírus de hepatite c (hcv), e, kit

Info

Publication number
BR112012021795A2
BR112012021795A2 BR112012021795A BR112012021795A BR112012021795A2 BR 112012021795 A2 BR112012021795 A2 BR 112012021795A2 BR 112012021795 A BR112012021795 A BR 112012021795A BR 112012021795 A BR112012021795 A BR 112012021795A BR 112012021795 A2 BR112012021795 A2 BR 112012021795A2
Authority
BR
Brazil
Prior art keywords
subject
virus
identifying
risk
hepatitis
Prior art date
Application number
BR112012021795A
Other languages
English (en)
Portuguese (pt)
Inventor
Vincent Agnello
Original Assignee
Vincent Agnello
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vincent Agnello filed Critical Vincent Agnello
Publication of BR112012021795A2 publication Critical patent/BR112012021795A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
BR112012021795A 2010-03-01 2011-02-28 método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica e malignidade de célula b associadas ao vírus de hepatite c (hvc), método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica ou malignidade de célula b associadas à infecção por vírus de hepatite c (hvc), método de tratamento de vasculite crioglobulinêmica e malignidade de célula b associadas a hcv em um sujeito, método de identificação de um sujeito que se encontra com risco de desenvolver malignidade associada ao vírus de hepatite c (hcv), e, kit BR112012021795A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30916110P 2010-03-01 2010-03-01
PCT/US2011/026455 WO2011109285A2 (en) 2010-03-01 2011-02-28 Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients

Publications (1)

Publication Number Publication Date
BR112012021795A2 true BR112012021795A2 (pt) 2016-05-17

Family

ID=44542788

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012021795A BR112012021795A2 (pt) 2010-03-01 2011-02-28 método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica e malignidade de célula b associadas ao vírus de hepatite c (hvc), método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica ou malignidade de célula b associadas à infecção por vírus de hepatite c (hvc), método de tratamento de vasculite crioglobulinêmica e malignidade de célula b associadas a hcv em um sujeito, método de identificação de um sujeito que se encontra com risco de desenvolver malignidade associada ao vírus de hepatite c (hcv), e, kit

Country Status (7)

Country Link
US (3) US9719141B2 (https=)
EP (1) EP2542892A4 (https=)
JP (1) JP6095984B2 (https=)
AU (1) AU2011223906B2 (https=)
BR (1) BR112012021795A2 (https=)
CA (1) CA2791676A1 (https=)
WO (1) WO2011109285A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103184216B (zh) * 2011-12-27 2015-03-18 深圳华大基因科技有限公司 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途
US11781112B2 (en) 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
RU2642626C1 (ru) * 2016-11-03 2018-01-25 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ прогнозирования развития криоглобулинемического васкулита у больных хроническим гепатитом с
US11026625B2 (en) 2017-08-08 2021-06-08 Fresenius Medical Care Holdings, Inc. Systems and methods for treating and estimating progression of chronic kidney disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020049A1 (it) 2002-01-30 2003-07-30 Biostrands S R L Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro.
US8178303B2 (en) 2003-12-04 2012-05-15 Wake Forest University Health Sciences Increasing the speed of cryoglobulin precipitation
EP1801116A1 (en) 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV replicon shuttle vectors

Also Published As

Publication number Publication date
WO2011109285A2 (en) 2011-09-09
US9719141B2 (en) 2017-08-01
EP2542892A2 (en) 2013-01-09
US20160083801A1 (en) 2016-03-24
JP6095984B2 (ja) 2017-03-15
CA2791676A1 (en) 2011-09-09
WO2011109285A3 (en) 2012-01-19
EP2542892A4 (en) 2013-11-27
US20130052206A1 (en) 2013-02-28
AU2011223906A1 (en) 2012-09-13
CN102859360A (zh) 2013-01-02
JP2013521497A (ja) 2013-06-10
US20180002763A1 (en) 2018-01-04
AU2011223906B2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
EP2340481A4 (en) CACHE-SAVING RUNTIME-GENERATED CODE
EP2016195A4 (en) BIOMARKERS FOR HEPATITIS C VIRUS INFECTION
BRPI0716647A2 (pt) processos de tratamento de mieloma múltiplo utilizando terapias de combinação baseadas em anticorpos anti-cs1
MX2009005942A (es) Anticuerpos recombinantes contra el virus de hepatitis c y metodos para obtener y usar los mismos.
BR112012001931A2 (pt) métodos para diagnosticar ou prever o resultado de hepatite c em pacientes infectados com hcv
DK1976516T3 (da) Behandling af viral hepatitis
BR112012000913A2 (pt) processador de informação, método de processamento de informação, e, programa.
ATE511674T1 (de) Verfahren und system zur auflösung gleichzeitig vorgegebener verzweigungsinstruktionen
BR112012021795A2 (pt) método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica e malignidade de célula b associadas ao vírus de hepatite c (hvc), método de identificação de um sujeito que se encontra com risco de desenvolver vasculite crioglobulinêmica ou malignidade de célula b associadas à infecção por vírus de hepatite c (hvc), método de tratamento de vasculite crioglobulinêmica e malignidade de célula b associadas a hcv em um sujeito, método de identificação de um sujeito que se encontra com risco de desenvolver malignidade associada ao vírus de hepatite c (hcv), e, kit
EP2031936A4 (en) MICROWAVE HEATING DEVICE
DK2054428T3 (da) Udvikling af bestanddele til denque-virus-vaccine
GB0706489D0 (en) Error recovery following speculative execution with an instruction processing pipeline
BRPI0907729A2 (pt) Métodos para tratar doenças mediadas pela catepsina b em um mamífero e para tratar um indivíduo diagnosticado tanto com hcv quanto com fribose em um mamífero
BR112012027151A2 (pt) diagnósticode infecções virais por detecção de dna viral, genômico e infeccioso por molecular combing
EP2343952A4 (en) Induction heating cooker
DE602006006990D1 (de) SIMD-Prozessorarchitektur mit gruppierten Verarbeitungseinheiten
BR112012015299A2 (pt) "camisola de paciente em um dispositivo de aquecimento de paciente, método de aquecimento de um paciente com um dispositivo de aquecimento e método de fabricação de dispositivo de aquecimento"
BRPI0716136A2 (pt) sistema de cozimento de wafer por induÇço
EP1723238A4 (en) MODIFIED ONCOLYTIC VIRUSES
BRPI0621937A2 (pt) suplemento alimentar baseado em licopeno biológico e processo de co-extração de licopeno biológico
FI20075831A0 (fi) Rannetuella varustettu urheilukäsine
BRPI1008087A2 (pt) processo de conferir segurança a um objeto opaco ou translúcido, colorido ou não e objeto autenticável
BRPI0903904A2 (pt) Unidade e método de processamento de informação, e, programa
DE502007003140D1 (de) Schlüsseltransferschalter system und methode
EP2205617A4 (en) HEPATITIS B-VIRUS-SPECIFIC OLIGONUCLEOTIDE SEQUENCES

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2619 DE 16-03-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.